U.S. Stem Cell, Inc. (USRM)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jul 30, 2025
Market Cap662.00
Revenue (ttm)82.05K
Net Income (ttm)-2.86M
Shares Out661.51M
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,431
Average Volume128,700
Open0.0000
Previous Close0.0000
Day's Range0.0000 - 0.0000
52-Week Range0.0000 - 0.0002
Beta-111.07
RSI39.13
Earnings DateAug 7, 2025

About Marinus Pharmaceuticals

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol USRM
Full Company Profile

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$2.86 million, -13.06% less than in 2021.

Financial Statements

News

Mark Borman Appointed Chairman of the Board of USRM

SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutio...

3 years ago - Accesswire